184 related articles for article (PubMed ID: 30229683)
1. Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer.
Lu H; Qin J; Han N; Xie F; Gong L; Li C
Integr Cancer Ther; 2018 Dec; 17(4):1109-1114. PubMed ID: 30229683
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of Shengjiang Xiexin decoction in prophylaxis of chemotherapy-related diarrhea in small cell lung cancer patients: study protocol for a multicenter randomized controlled trial.
Deng C; Lou Y; Gao Y; Deng B; Su F; Jia L
Trials; 2020 May; 21(1):370. PubMed ID: 32357899
[TBL] [Abstract][Full Text] [Related]
3. Banxia Xiexin decoction combined with 5-ASA protects against CPT-11-induced intestinal dysfunction in rats via inhibiting TLR4/NF-κB signaling pathway.
Zou Y; Wang Y; Zhou W; Pei J
Immun Inflamm Dis; 2024 Jun; 12(6):e1208. PubMed ID: 38860759
[TBL] [Abstract][Full Text] [Related]
4. Identification of the bioactive components of Banxia Xiexin Decoction that protect against CPT-11-induced intestinal toxicity via UPLC-based spectrum-effect relationship analyses.
Shi JW; Li ZZ; Wu JS; Jin WY; Chang XY; Sun H; Dong L; Jiang ZP; Shi Y
J Ethnopharmacol; 2021 Feb; 266():113421. PubMed ID: 33022337
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of the Efficacy of Irinotecan in the Second-line Treatment of Refractory and Relapsed Small Cell Lung Cancer].
Xing H; Zhang J; Ge F; Yu X; Bian H; Zhang F; Fang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):167-172. PubMed ID: 33819966
[TBL] [Abstract][Full Text] [Related]
6. Baicalein, a component of banxia xiexin decoction, alleviates CPT-11-induced gastrointestinal dysfunction by inhibiting ALOX15-mediated ferroptosis.
Pei J; Zou Y; Zhou W; Wang Y
Chem Biol Drug Des; 2023 Dec; 102(6):1568-1577. PubMed ID: 37735740
[TBL] [Abstract][Full Text] [Related]
7. [Potential molecular mechanism of Banxia Xiexin Decoction in treatment of colon cancer based on network pharmacology and molecular docking technology].
Luo YT; Lin LF; Liu YL; Shi GL; Wu YQ; Yang AH; Li H
Zhongguo Zhong Yao Za Zhi; 2020 Dec; 45(23):5753-5761. PubMed ID: 33496116
[TBL] [Abstract][Full Text] [Related]
8. [Effect of Shengjiang Xiexin Decoction on the Repair of Damaged Rat Intestinal Mucosa after Irinotecan Chemotherapy].
Wang J; Jia LQ; Tan HY; Pan L; Yu LL; Deng B
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Oct; 35(10):1236-43. PubMed ID: 26677677
[TBL] [Abstract][Full Text] [Related]
9. Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Morise M; Niho S; Umemura S; Matsumoto S; Yoh K; Goto K; Ohmatsu H; Ohe Y
Jpn J Clin Oncol; 2014 Sep; 44(9):846-51. PubMed ID: 25057092
[TBL] [Abstract][Full Text] [Related]
10. [UPLC/Q-TOF-MS(E) based analysis of chemical composition of banxia xiexin decoction].
Yan LL; Shi JW; Wang JF; Shi Y
Yao Xue Xue Bao; 2013 Apr; 48(4):526-31. PubMed ID: 23833940
[TBL] [Abstract][Full Text] [Related]
11. Traditional Chinese medicine Gegen Qinlian decoction ameliorates irinotecan chemotherapy-induced gut toxicity in mice.
Wu Y; Wang D; Yang X; Fu C; Zou L; Zhang J
Biomed Pharmacother; 2019 Jan; 109():2252-2261. PubMed ID: 30551482
[TBL] [Abstract][Full Text] [Related]
12. Chinese herbal medicine for irinotecan-induced diarrhea: A systematic review and meta-analysis.
Lin X; Fang Y; Cheng Y; Wang Q
Explore (NY); 2024; 20(2):158-167. PubMed ID: 37640591
[TBL] [Abstract][Full Text] [Related]
13. A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer.
Alamgeer M; Neil Watkins D; Banakh I; Kumar B; Gough DJ; Markman B; Ganju V
Invest New Drugs; 2018 Apr; 36(2):288-298. PubMed ID: 29277856
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of irinotecan plus nedaplatin (INP) in treating patients with extensive stage small cell lung cancer.
Li C; Huang XE; Li Y
Asian Pac J Cancer Prev; 2011; 12(2):487-90. PubMed ID: 21545218
[TBL] [Abstract][Full Text] [Related]
15. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
Yun F; Lulu M; Zhiyu H; Lei G; Haifeng Y; Tao L; Haiyan Y; Conghua X
J Cancer Res Ther; 2014 Nov; 10 Suppl():C195-200. PubMed ID: 25450281
[TBL] [Abstract][Full Text] [Related]
16. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.
Kawahara M; Kubo A; Komuta K; Fujita Y; Sasaki Y; Fukushima M; Daimon T; Furuse K; Mishima M; Mio T
J Thorac Oncol; 2012 Dec; 7(12):1845-1849. PubMed ID: 22139390
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer.
Seto Z; Takata N; Murayama N; Tokui K; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Matsui S; Inomata M
Tumori; 2021 Dec; 107(6):536-541. PubMed ID: 34847814
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.
Miyamoto M; Takano M; Kuwahara M; Soyama H; Kato K; Matuura H; Sakamoto T; Takasaki K; Aoyama T; Yoshikawa T; Furuya K
Cancer Chemother Pharmacol; 2018 Jan; 81(1):111-117. PubMed ID: 29124328
[TBL] [Abstract][Full Text] [Related]
20. Banxia Xiexin Decoction in the treatment of Hp-associated peptic ulcer: A protocol for systematic review and meta-analysis.
Zhu W; Li J; Shen H
Medicine (Baltimore); 2021 Jan; 100(2):e24105. PubMed ID: 33466180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
